Hepion Pharmaceuticals, Inc. (HEPA) Form 10-Q — May 14, 2026
Hepion Pharmaceuticals reported a net loss of $810,791 for the three months ended March 31, 2026, with no revenue generated. The company disclosed substantial doubt about its ability to continue as a going concern, citing an accumulated deficit of $246.9 million and only $2.6 million in cash. The filing reveals material weaknesses in internal controls, including ineffective segregation of duties and lack of proper review of complex accounting transactions. Management stated that remediation requires additional capital, which is not guaranteed.
Key figures
- Revenue
- 0
- Total Assets
- 2705503
- Cash Position
- 2602580
- Shares Outstanding
- 29119317
- Working capital
- 2000000
- Stetz base salary
- 250000
- Accumulated deficit
- 246908447
- Lopriore base salary
- 280000
- Private placement price
- 0.04
- Private placement shares
- 17500000
- Private placement proceeds
- 700000
Price after filing
Close on the filing date to close N calendar days later (from $0.10). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.